Upper Extremity Motor Assessment in Ataxia | ICAR 2022

In a recent publication in collaboration with the Department of Neurology at Massachusetts General Hospital, we demonstrated the use of BioSensics wearable devices for objective assessment of upper extremity motor functions in spinocerebellar ataxia. Our findings complement our previous published work in assessment of gait and balance impairment in ataxia. BioSensics wearable devices and digital health technologies can assist eliminating subjectivity and inter-rater variabilities in assessing motor, speech and cognitive function in neurological disorders.

BioSensics is excited to sponsor and attend the International Congress for Ataxia Research (ICAR) this week. We will also present a poster related to our work on objective assessment of motor impairment in ataxia (See below). In addition, we will discuss our new collaborative project with the Friedreich's Ataxia Research Alliance and University of Pennsylvania to develop an at-home monitoring solution for patients with Friedrich's ataxia using PAMSys. 

PAMSys is the most advanced wearable sensor for monitoring walking parameters, posture and postural transition, sedentary behavior, sleep and sleep quality, and falls during activities of daily living. PAMSys measures 40+ independent parameters of physical activity and has been used in 10+ clinical trials for collecting secondary and primary endpoints. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.